Global Liposome Assisted Drug Delivery Market

Liposome Assisted Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others), Application (Fungal Infection Therapy, Cancer and Tumor Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores), Liposomes Type (Simple Liposomes, Formulated Liposomes, Vaccines) Players and Region - Global Market Outlook to 2030

Liposome Assisted Drug Delivery Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 8.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Liposome Assisted Drug Delivery Market Scope
Liposome refers to a spherical vesicle that has at least one lipid bilayer. In healthcare, liposomes are used as a vehicle for the delivery of drugs and nutrients. It is estimated that increased research and development in the healthcare sector worldwide will provide significant expansion opportunities in the global market for liposomal drug delivery in the coming years. Liposomes are gaining traction across the health care sector as they can act as potential antiviral agents that help reduce the economic burden and social impact of the COVID-19 pandemic. Companies in the liposomal drug delivery market are focused on developing liposomes that offer high solubility and longer circulation time to advance drug release profiles.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledSpectrum Pharmaceuticals, Inc. (United States), Astellas Pharma, Inc. (Japan), Gilead Sciences, Inc. (United States), Celsion Corporation (United States), Ipsen Pharma (France), Pacira BioSciences, Inc. (United States), Luye Pharma Group (China), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan) and Johnson & Johnson (United States)
CAGR8.5%


The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Liposome Assisted Drug Delivery market throughout the predicted period.

Spectrum Pharmaceuticals, Inc. (United States), Astellas Pharma, Inc. (Japan), Gilead Sciences, Inc. (United States), Celsion Corporation (United States), Ipsen Pharma (France), Pacira BioSciences, Inc. (United States), Luye Pharma Group (China), Novartis AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan) and Johnson & Johnson (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Liposome Assisted Drug Delivery market by Type , by Application (Fungal Infection Therapy, Cancer and Tumor Therapy and Others) and Region with country level break-up.

On the basis of geography, the market of Liposome Assisted Drug Delivery has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In January 2022, Sun Pharma Advanced Research Company was manufacturing a liposome-encapsulated formulation of the taxane compound paclitaxel (a tubulin inhibitor) for the treatment of breast cancer.
In June 2022, Endo International plc's subsidiary Endo Ventures Limited (EVL) entered into an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in phase 3 development for the treatment of osteoarthritis knee pain.
In August 2018, the United States Food and Drug Administration (FDA), has published its final guidance for the industry on liposome drug products in April 2018. In addition, it finalizes the revised draft guidance for industry Liposome Drug Products

Influencing Trend:
Adoption of Liposome in Clinics Due To Low Toxicity and High Efficiency

Market Growth Drivers:
Increase in the Understanding of Targeted Drug Delivery System and Increase in the Number of Patients Suffering From Solid Tumors and Macrophages

Challenges:
Short Half-Life of Liposome

Restraints:
Low Solubility in Body and High Cost of Production

Opportunities:
Continuous Research and Development in Design of Liposome for New Biotechnology Products Would Enhance the Market Growth

Key Target Audience
Providers of Liposome Assisted Drug Delivery, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others

Report Objectives / Segmentation Covered

By Type
  • Liposomal Doxorubicin
  • Liposomal Amphoteracin B
  • Liposomal Paclitaxel
  • Others
By Application
  • Fungal Infection Therapy
  • Cancer and Tumor Therapy
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies
  • Drug Stores

By Liposomes Type
  • Simple Liposomes
  • Formulated Liposomes
  • Vaccines

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Understanding of Targeted Drug Delivery System
      • 3.2.2. Increase in the Number of Patients Suffering From Solid Tumors and Macrophages
    • 3.3. Market Challenges
      • 3.3.1. Short Half-Life of Liposome
    • 3.4. Market Trends
      • 3.4.1. Adoption of Liposome in Clinics Due To Low Toxicity and High Efficiency
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liposome Assisted Drug Delivery, by Type, Application, Distribution Channel, Liposomes Type and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Liposome Assisted Drug Delivery (Value)
      • 5.2.1. Global Liposome Assisted Drug Delivery by: Type (Value)
        • 5.2.1.1. Liposomal Doxorubicin
        • 5.2.1.2. Liposomal Amphoteracin B
        • 5.2.1.3. Liposomal Paclitaxel
        • 5.2.1.4. Others
      • 5.2.2. Global Liposome Assisted Drug Delivery by: Application (Value)
        • 5.2.2.1. Fungal Infection Therapy
        • 5.2.2.2. Cancer and Tumor Therapy
        • 5.2.2.3. Others
      • 5.2.3. Global Liposome Assisted Drug Delivery by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Mail Order Pharmacies
        • 5.2.3.4. Drug Stores
      • 5.2.4. Global Liposome Assisted Drug Delivery by: Liposomes Type (Value)
        • 5.2.4.1. Simple Liposomes
        • 5.2.4.2. Formulated Liposomes
        • 5.2.4.3. Vaccines
      • 5.2.5. Global Liposome Assisted Drug Delivery Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Liposome Assisted Drug Delivery (Price)
      • 5.3.1. Global Liposome Assisted Drug Delivery by: Type (Price)
  • 6. Liposome Assisted Drug Delivery: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Spectrum Pharmaceuticals, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma, Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gilead Sciences, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Celsion Corporation (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Ipsen Pharma (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pacira BioSciences, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Luye Pharma Group (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Johnson & Johnson (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Liposome Assisted Drug Delivery Sale, by Type, Application, Distribution Channel, Liposomes Type and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Liposome Assisted Drug Delivery (Value)
      • 7.2.1. Global Liposome Assisted Drug Delivery by: Type (Value)
        • 7.2.1.1. Liposomal Doxorubicin
        • 7.2.1.2. Liposomal Amphoteracin B
        • 7.2.1.3. Liposomal Paclitaxel
        • 7.2.1.4. Others
      • 7.2.2. Global Liposome Assisted Drug Delivery by: Application (Value)
        • 7.2.2.1. Fungal Infection Therapy
        • 7.2.2.2. Cancer and Tumor Therapy
        • 7.2.2.3. Others
      • 7.2.3. Global Liposome Assisted Drug Delivery by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Mail Order Pharmacies
        • 7.2.3.4. Drug Stores
      • 7.2.4. Global Liposome Assisted Drug Delivery by: Liposomes Type (Value)
        • 7.2.4.1. Simple Liposomes
        • 7.2.4.2. Formulated Liposomes
        • 7.2.4.3. Vaccines
      • 7.2.5. Global Liposome Assisted Drug Delivery Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Liposome Assisted Drug Delivery (Price)
      • 7.3.1. Global Liposome Assisted Drug Delivery by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liposome Assisted Drug Delivery: by Type(USD Million)
  • Table 2. Liposome Assisted Drug Delivery Liposomal Doxorubicin , by Region USD Million (2018-2023)
  • Table 3. Liposome Assisted Drug Delivery Liposomal Amphoteracin B , by Region USD Million (2018-2023)
  • Table 4. Liposome Assisted Drug Delivery Liposomal Paclitaxel , by Region USD Million (2018-2023)
  • Table 5. Liposome Assisted Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 6. Liposome Assisted Drug Delivery: by Application(USD Million)
  • Table 7. Liposome Assisted Drug Delivery Fungal Infection Therapy , by Region USD Million (2018-2023)
  • Table 8. Liposome Assisted Drug Delivery Cancer and Tumor Therapy , by Region USD Million (2018-2023)
  • Table 9. Liposome Assisted Drug Delivery Others , by Region USD Million (2018-2023)
  • Table 10. Liposome Assisted Drug Delivery: by Distribution Channel(USD Million)
  • Table 11. Liposome Assisted Drug Delivery Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 12. Liposome Assisted Drug Delivery Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Liposome Assisted Drug Delivery Mail Order Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Liposome Assisted Drug Delivery Drug Stores , by Region USD Million (2018-2023)
  • Table 15. Liposome Assisted Drug Delivery: by Liposomes Type(USD Million)
  • Table 16. Liposome Assisted Drug Delivery Simple Liposomes , by Region USD Million (2018-2023)
  • Table 17. Liposome Assisted Drug Delivery Formulated Liposomes , by Region USD Million (2018-2023)
  • Table 18. Liposome Assisted Drug Delivery Vaccines , by Region USD Million (2018-2023)
  • Table 19. South America Liposome Assisted Drug Delivery, by Country USD Million (2018-2023)
  • Table 20. South America Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 21. South America Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 22. South America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 23. South America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 24. Brazil Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 25. Brazil Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 26. Brazil Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 27. Brazil Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 28. Argentina Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 29. Argentina Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 30. Argentina Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 31. Argentina Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 32. Rest of South America Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 35. Rest of South America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 36. Asia Pacific Liposome Assisted Drug Delivery, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 40. Asia Pacific Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 41. China Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 42. China Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 43. China Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 44. China Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 45. Japan Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 46. Japan Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 47. Japan Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 48. Japan Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 49. India Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 50. India Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 51. India Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 52. India Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 53. South Korea Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 54. South Korea Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 55. South Korea Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 56. South Korea Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 57. Taiwan Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 58. Taiwan Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 59. Taiwan Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 60. Taiwan Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 61. Australia Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 62. Australia Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 63. Australia Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 64. Australia Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 69. Europe Liposome Assisted Drug Delivery, by Country USD Million (2018-2023)
  • Table 70. Europe Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 71. Europe Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 72. Europe Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 73. Europe Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 74. Germany Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 75. Germany Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 76. Germany Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 77. Germany Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 78. France Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 79. France Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 80. France Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 81. France Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 82. Italy Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 83. Italy Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 84. Italy Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 85. Italy Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 86. United Kingdom Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 89. United Kingdom Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 90. Netherlands Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 91. Netherlands Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 92. Netherlands Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 93. Netherlands Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 94. Rest of Europe Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 97. Rest of Europe Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 98. MEA Liposome Assisted Drug Delivery, by Country USD Million (2018-2023)
  • Table 99. MEA Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 100. MEA Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 101. MEA Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 102. MEA Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 103. Middle East Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 104. Middle East Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 105. Middle East Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 106. Middle East Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 107. Africa Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 108. Africa Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 109. Africa Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 110. Africa Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 111. North America Liposome Assisted Drug Delivery, by Country USD Million (2018-2023)
  • Table 112. North America Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 113. North America Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 114. North America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 115. North America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 116. United States Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 117. United States Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 118. United States Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 119. United States Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 120. Canada Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 121. Canada Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 122. Canada Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 123. Canada Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 124. Mexico Liposome Assisted Drug Delivery, by Type USD Million (2018-2023)
  • Table 125. Mexico Liposome Assisted Drug Delivery, by Application USD Million (2018-2023)
  • Table 126. Mexico Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2018-2023)
  • Table 127. Mexico Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2018-2023)
  • Table 128. Liposome Assisted Drug Delivery: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Liposome Assisted Drug Delivery: by Type(USD Million)
  • Table 140. Liposome Assisted Drug Delivery Liposomal Doxorubicin , by Region USD Million (2025-2030)
  • Table 141. Liposome Assisted Drug Delivery Liposomal Amphoteracin B , by Region USD Million (2025-2030)
  • Table 142. Liposome Assisted Drug Delivery Liposomal Paclitaxel , by Region USD Million (2025-2030)
  • Table 143. Liposome Assisted Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 144. Liposome Assisted Drug Delivery: by Application(USD Million)
  • Table 145. Liposome Assisted Drug Delivery Fungal Infection Therapy , by Region USD Million (2025-2030)
  • Table 146. Liposome Assisted Drug Delivery Cancer and Tumor Therapy , by Region USD Million (2025-2030)
  • Table 147. Liposome Assisted Drug Delivery Others , by Region USD Million (2025-2030)
  • Table 148. Liposome Assisted Drug Delivery: by Distribution Channel(USD Million)
  • Table 149. Liposome Assisted Drug Delivery Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 150. Liposome Assisted Drug Delivery Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 151. Liposome Assisted Drug Delivery Mail Order Pharmacies , by Region USD Million (2025-2030)
  • Table 152. Liposome Assisted Drug Delivery Drug Stores , by Region USD Million (2025-2030)
  • Table 153. Liposome Assisted Drug Delivery: by Liposomes Type(USD Million)
  • Table 154. Liposome Assisted Drug Delivery Simple Liposomes , by Region USD Million (2025-2030)
  • Table 155. Liposome Assisted Drug Delivery Formulated Liposomes , by Region USD Million (2025-2030)
  • Table 156. Liposome Assisted Drug Delivery Vaccines , by Region USD Million (2025-2030)
  • Table 157. South America Liposome Assisted Drug Delivery, by Country USD Million (2025-2030)
  • Table 158. South America Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 159. South America Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 160. South America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 161. South America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 162. Brazil Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 163. Brazil Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 164. Brazil Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 165. Brazil Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 166. Argentina Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 167. Argentina Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 168. Argentina Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 169. Argentina Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 170. Rest of South America Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 171. Rest of South America Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 172. Rest of South America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 173. Rest of South America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 174. Asia Pacific Liposome Assisted Drug Delivery, by Country USD Million (2025-2030)
  • Table 175. Asia Pacific Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 176. Asia Pacific Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 177. Asia Pacific Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 178. Asia Pacific Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 179. China Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 180. China Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 181. China Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 182. China Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 183. Japan Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 184. Japan Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 185. Japan Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 186. Japan Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 187. India Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 188. India Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 189. India Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 190. India Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 191. South Korea Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 192. South Korea Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 193. South Korea Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 194. South Korea Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 195. Taiwan Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 196. Taiwan Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 197. Taiwan Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 198. Taiwan Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 199. Australia Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 200. Australia Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 201. Australia Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 202. Australia Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 207. Europe Liposome Assisted Drug Delivery, by Country USD Million (2025-2030)
  • Table 208. Europe Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 209. Europe Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 210. Europe Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 211. Europe Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 212. Germany Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 213. Germany Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 214. Germany Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 215. Germany Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 216. France Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 217. France Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 218. France Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 219. France Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 220. Italy Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 221. Italy Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 222. Italy Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 223. Italy Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 224. United Kingdom Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 225. United Kingdom Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 226. United Kingdom Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 227. United Kingdom Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 228. Netherlands Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 229. Netherlands Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 230. Netherlands Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 231. Netherlands Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 232. Rest of Europe Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 233. Rest of Europe Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 234. Rest of Europe Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 235. Rest of Europe Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 236. MEA Liposome Assisted Drug Delivery, by Country USD Million (2025-2030)
  • Table 237. MEA Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 238. MEA Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 239. MEA Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 240. MEA Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 241. Middle East Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 242. Middle East Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 243. Middle East Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 244. Middle East Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 245. Africa Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 246. Africa Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 247. Africa Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 248. Africa Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 249. North America Liposome Assisted Drug Delivery, by Country USD Million (2025-2030)
  • Table 250. North America Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 251. North America Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 252. North America Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 253. North America Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 254. United States Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 255. United States Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 256. United States Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 257. United States Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 258. Canada Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 259. Canada Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 260. Canada Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 261. Canada Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 262. Mexico Liposome Assisted Drug Delivery, by Type USD Million (2025-2030)
  • Table 263. Mexico Liposome Assisted Drug Delivery, by Application USD Million (2025-2030)
  • Table 264. Mexico Liposome Assisted Drug Delivery, by Distribution Channel USD Million (2025-2030)
  • Table 265. Mexico Liposome Assisted Drug Delivery, by Liposomes Type USD Million (2025-2030)
  • Table 266. Liposome Assisted Drug Delivery: by Type(USD/Units)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liposome Assisted Drug Delivery: by Type USD Million (2018-2023)
  • Figure 5. Global Liposome Assisted Drug Delivery: by Application USD Million (2018-2023)
  • Figure 6. Global Liposome Assisted Drug Delivery: by Distribution Channel USD Million (2018-2023)
  • Figure 7. Global Liposome Assisted Drug Delivery: by Liposomes Type USD Million (2018-2023)
  • Figure 8. South America Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 9. Asia Pacific Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 10. Europe Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 11. MEA Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 12. North America Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 13. Global Liposome Assisted Drug Delivery: by Type USD/Units (2018-2023)
  • Figure 14. Global Liposome Assisted Drug Delivery share by Players 2023 (%)
  • Figure 15. Global Liposome Assisted Drug Delivery share by Players (Top 3) 2023(%)
  • Figure 16. Global Liposome Assisted Drug Delivery share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Spectrum Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Spectrum Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2023
  • Figure 22. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Gilead Sciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Celsion Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 25. Celsion Corporation (United States) Revenue: by Geography 2023
  • Figure 26. Ipsen Pharma (France) Revenue, Net Income and Gross profit
  • Figure 27. Ipsen Pharma (France) Revenue: by Geography 2023
  • Figure 28. Pacira BioSciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pacira BioSciences, Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Luye Pharma Group (China) Revenue, Net Income and Gross profit
  • Figure 31. Luye Pharma Group (China) Revenue: by Geography 2023
  • Figure 32. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 34. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2023
  • Figure 36. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 37. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 38. Global Liposome Assisted Drug Delivery: by Type USD Million (2025-2030)
  • Figure 39. Global Liposome Assisted Drug Delivery: by Application USD Million (2025-2030)
  • Figure 40. Global Liposome Assisted Drug Delivery: by Distribution Channel USD Million (2025-2030)
  • Figure 41. Global Liposome Assisted Drug Delivery: by Liposomes Type USD Million (2025-2030)
  • Figure 42. South America Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 43. Asia Pacific Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 44. Europe Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 45. MEA Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 46. North America Liposome Assisted Drug Delivery Share (%), by Country
  • Figure 47. Global Liposome Assisted Drug Delivery: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Spectrum Pharmaceuticals, Inc. (United States)
  • Astellas Pharma, Inc. (Japan)
  • Gilead Sciences, Inc. (United States)
  • Celsion Corporation (United States)
  • Ipsen Pharma (France)
  • Pacira BioSciences, Inc. (United States)
  • Luye Pharma Group (China)
  • Novartis AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Johnson & Johnson (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 232 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liposome Assisted Drug Delivery Market Quantitative research analysis
Global Liposome Assisted Drug Delivery Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Liposome Assisted Drug Delivery Market are by type [Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel and Others], by end use application [Fungal Infection Therapy, Cancer and Tumor Therapy and Others].
The Liposome Assisted Drug Delivery Market is gaining popularity and expected to see strong valuation by 2030.
  • Increase in the Understanding of Targeted Drug Delivery System
  • Increase in the Number of Patients Suffering From Solid Tumors and Macrophages

Know More About Global Liposome Assisted Drug Delivery Market Report?

Have a Query? Click Here

Other Related Reports

Heart Disease Drugs Comprehensive Study by Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), Disease (Hypertension, Hyperlipidemia, Coronary Artery Disease...
$ 3650
Cholesterol Drug Comprehensive Study by Type (Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin, Pitavastatin (Livalo), Pravastatin (Pravachol), Rosuvastatin calcium (Crestor), Simvastatin (Zo...
$ 3750
Smart Pill Dispenser Comprehensive Study by Type (Centralized automated dispensing system (Robots and Carousels), Decentralized automated dispensing system (Pharmacy-based automated dispensing system...
$ 3650
Certolizumab pegol Comprehensive Study by Type (Single-dose Vial, Single-dose Prefilled Syringe), Application (Crohn's Disease, Active Rheumatoid Arthritis, Active Psoriatic Arthritis), Distribution ...
$ 3450
Anti-diabetic Medication Comprehensive Study by Type (Insulin (Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin), Drug class (Alpha gluc...
$ 3750
Pyrazinamide Comprehensive Study by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Adult, Pediatric)
$ 3500